Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
Expected New Patent Based on Extensive Review of Data and Information
基于对数据和信息的广泛审查,有望获得新专利
GLEN ALLEN, Va., July 31, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of a new patent application for AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day). The patent, assuming granted, is expected to protect Adial's core assets through at least 2044.
弗吉尼亚州格伦艾伦,2024年7月31日(GLOBE NEWSWIRE)——专注于开发治疗和预防成瘾及相关疾病疗法的临床阶段生物制药公司Adial Pharmicals, Inc.(纳斯达克股票代码:ADIL)(“Adial” 或 “公司”)宣布为该公司主要研究性基因靶向血清素-3AD04提交新的专利申请受体拮抗剂,用于治疗大量饮酒患者(定义为每天饮酒
Cary Claiborne, President and Chief Executive Officer of Adial commented, "As we continue to advance the AD04 program with the progress of our pharmacokinetics study of AD04, this new patent application and it's expected approval will extend protection of the core assets of Adial out to at least 2044. This application is the result of an extensive examination of data and information which occurred after Adial hired new patent counsel to bolster and leverage the company's intellectual property portfolio."
Adial总裁兼首席执行官Cary Claiborne评论说:“随着AD04药代动力学研究的进展,我们继续推进AD04计划,这项新的专利申请及其预期的批准将把对Adial核心资产的保护至少延长至2044年。该申请是在Adial聘请了新的专利律师来加强和利用公司的知识产权组合之后对数据和信息进行了广泛审查的结果。”
About Adial Pharmaceuticals, Inc.
关于阿迪尔制药公司
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company's companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at .
Adial Pharmaceuticals是一家临床阶段的生物制药公司,专注于开发成瘾和相关疾病的治疗方法。该公司的主要研究性新药产品AD04是一种基因靶向血清素-3受体拮抗剂,用于治疗重度饮酒患者酒精使用障碍(AUD),最近在该公司ONWARD的关键性3期临床试验中进行了研究,该试验旨在对使用公司的伴随诊断基因测试确定的具有某些靶标基因型的受试者可能治疗澳元。ONWARD在减少大量饮酒患者的饮酒量方面显示出令人鼓舞的结果,没有明显的安全性或耐受性问题。AD04还被认为有可能治疗其他成瘾性疾病,例如阿片类药物使用障碍、赌博和肥胖。其他信息可在以下网址获得。
Forward-Looking Statements
前瞻性陈述
This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the Company's new patent application for AD04, the patent protecting Adial's core assets out to at least 2044 once granted, the patent being granted ,continuing to advance the AD04 program and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to protect our core assets with the new patent, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
本通信包含美国联邦证券法所指的某些 “前瞻性陈述”。此类陈述基于各种事实,并利用许多重要假设得出,并受已知和未知的风险、不确定性和其他因素的影响,这些因素可能导致实际业绩、业绩或成就与此类前瞻性陈述所表达或暗示的任何未来业绩、业绩或成就存在重大差异。前后跟或以其他方式包含 “相信”、“期望”、“预期”、“打算”、“项目”、“估计”、“计划” 等类似表述或 “将”、“应该”、“将”、“可能” 和 “可能” 等未来或条件动词的陈述在本质上通常是前瞻性的,而不是历史事实,尽管并非所有前瞻性陈述都包括前述内容。前瞻性陈述包括有关公司新的AD04专利申请、保护Adial核心资产的专利一旦获得授权、专利的授权、继续推进AD04计划以及AD04治疗阿片类药物使用障碍、赌博和肥胖等其他成瘾性疾病的潜力的陈述。此处包含的任何前瞻性陈述都反映了我们当前的观点,它们涉及某些风险和不确定性,包括我们利用新专利保护核心资产的能力、我们推行监管战略的能力、推进持续合作讨论的能力、我们获得监管部门批准以将候选产品商业化或遵守现行监管要求的能力、我们开发战略合作机会和维持合作的能力、我们获得或维持合作的能力为我们的研发活动提供资金所需的资本或补助金、我们按时完成临床试验并按预期取得预期结果和收益的能力、与我们针对特定适应症推广或商业化候选产品的能力相关的监管限制、候选产品在市场上的接受以及我们产品的成功开发、营销或销售、我们维持许可协议的能力、专利资产的持续维护和增长以及我们保留密钥的能力员工或维持我们在纳斯达克的上市。不应将这些风险解释为详尽无遗,应与我们在截至2023年12月31日止年度的10-k表年度报告、随后的10-Q表季度报告以及向美国证券交易委员会提交的8-k表最新报告中的其他警示声明一起阅读。任何前瞻性陈述仅代表其最初发表之日。除非法律要求,否则我们没有义务公开更新或修改任何前瞻性陈述,无论是由于新信息、未来事件、情况变化还是其他原因。
Contact:
联系人:
Crescendo Communications, LLC
克雷森多通讯有限责任公司
David Waldman / Alexandra Schilt
大卫·沃尔德曼/亚历山德拉·席尔特
Tel: 212-671-1020
电话:212-671-1020
Email: adil@crescendo-ir.com
电子邮件:adil@crescendo-ir.com